Last reviewed · How we verify

VarmX B.V. — Portfolio Competitive Intelligence Brief

VarmX B.V. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Usual Pharmacological Care Usual Pharmacological Care phase 3 Cardiovascular
VMX-C001 VMX-C001 phase 3 SGLT2 inhibitor SGLT2 Diabetes
UFH UFH phase 3 Low molecular weight heparin Antithrombin III Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADvantage Therapeutics · 1 shared drug class
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. AO GENERIUM · 1 shared drug class
  4. Aalborg University Hospital · 1 shared drug class
  5. Abbott · 1 shared drug class
  6. AceLink Therapeutics, Inc. · 1 shared drug class
  7. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  8. 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VarmX B.V.:

Cite this brief

Drug Landscape (2026). VarmX B.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/varmx-b-v. Accessed 2026-06-10.

Related